億緯鋰能(300014.SZ)與維他動力就機械人業務深度合作
內地鋰電公司億緯鋰能(300014.SZ)公布,與維他動力就機械人業務達成深度合作,雙方將基於用戶需求和機械人動力電池技術發展趨勢,推進具身智能產品化量產的進一步發展。
億緯鋰能於6月底時向聯交所遞交招股書,擬於香港主板上市,獨家保薦人為中信證券。若成功上市,將會是繼寧德時代(03750.HK)之後,另一間實現A+H上市的鋰電企業。根據初步招股文件,公司去年收入按年跌0.3%至486.15億元人民幣,純利按年升0.6%至40.76億元人民幣。公司預期上市集資淨額將用於匈牙利生產基地的持續建設及馬來西亞生產基地第三期建設提供部分資金支持,以及用於營運資金及一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.